Actinium Pharmaceuticals(ATNM) - 2022 Q4 - Annual Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol Name of exchange on which registered Common stock, par value $0.001 ATNM NYSE American Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ FORM 10-K (Mark One) ☒ Annual Report Under Section 13 or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition Report Under Section 13 or 15(d) ...